[ Price : $8.95]
FDA grants Partner Therapeutics a breakthrough therapy designation for zenocutuzumab-zbco and its use in treating cholangiocarcino...[ Price : $8.95]
Inhibrx Biosciences reports favorable data for treating chondrosarcoma with its antibody therapy ozekibart (INBRX-109).[ Price : $8.95]
FDA posts a two-item Form FDA-483 from an August inspection of Sumitomo Pharmas Suzuka, Japan, manufacturing facility.[ Price : $8.95]
An FDA payroll system error causes a paycheck delay for some FDA employees who are designated to continue working during the ongoi...[ Price : $8.95]
FDA approves Bayers Lynkuet (elinzanetant) to treat moderate to severe vasomotor symptoms associated with menopause.[ Price : $8.95]
Tango Therapeutics reports that new data from its ongoing Phase 1-2 study of vopimetostat (TNG462) showed early signs of efficacy ...[ Price : $8.95]
A ProPublica investigative report faults FDA for blocking information about foreign-made generic drugs that could help patients, d...[ Price : $8.95]
The CDER Office of New Drugs publishes a MAPP on the regulatory basis for refusing to file an NDA, sNDA, BLA, or sBLA.